Search results

  • Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

    SOMERSET, N.J.— (BUSINESS WIRE) —February 11, 2022— Legend Biotech Corporation(NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen […]

  • Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

    SOMERSET, N.J.— (BUSINESS WIRE) —January 4, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, will deliver the company presentation on Tuesday, January 11, 2022 at […]

  • Legend Biotech Announces Closing of Global Strategic LCAR-B38M CAR-T Cell Immunotherapy Collaboration with Janssen

    Legend to receive an upfront payment of $350 million, as well as additional development, production performance, regulatory and sales milestone payments Legend and Janssen to co-develop and co-promote CAR-T cell therapy for multiple myeloma Profits and costs to be shared 50/50 worldwide, exclusive Greater China where 70 percent to Legend and 30 percent to Janssen […]

  • Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022

    SOMERSET, N.J.— August 5, 2022— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, […]

  • Technology Platforms

    There is no guarantee that the agents discussed will receive health authority approval or become commercially available in any country for the uses being investigated.

  • Comprehensive Compliance Program

    COMPLIANCE PROGRAM DECLARATION Legend Biotech USA Inc. (“Legend”) is in compliance with its Comprehensive Compliance Program (“CCP”) and California Health & Safety Code §§ 119400-119402.  Our Comprehensive Compliance program, which is further described below, contains the elements of an effective compliance program identified in the “Compliance Program Guidance for Pharmaceutical Manufacturers” published by the Office […]

  • Scientific Publications

    The links provided below redirect to third-party websites that may require a subscription to access publications.

close

You are about to leave LegendBiotech.com

You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.